Introduction Chronic musculoskeletal pain often extends beyond pathology alone. Augmented central pain processing is linked to pain severity, persistence and treatment outcomes.
A practical clinical tool is needed to identify individuals likely to have persistent or worsening pain, likely due to augmented central pain mechanisms. Quantitative Sensory Testing (QST) offers mechanistic insight, while the Central Aspects of Pain (CAP) Questionnaire captures symptom profiles that potentially reflect central mechanisms.
Combining a brief clinical QST protocol with CAP may support early risk stratification and guide personalised pain management. Methods and analysis This prospective observational study will recruit 250 individuals with inflammatory arthritis, osteoarthritis, chronic low back pain or fibromyalgia from existing cohorts, primary or secondary care.
Participants will complete validated patient-reported outcomes at baseline, 6 and 12 weeks, with no additional intervention. The risk stratification tool completed at baseline will include clinical QST (Pressure Pain Threshold, Temporal Summation of Pain, Conditioned Pain Modulation), tender point count and the CAP questionnaire.
BMJ Open published a clinical update in Research Highlights on 18 May 2026.
The item focuses on Assessing central nervous system contributions to accelerate musculoskeletal pain diagnosis and treatment (AsCent): protocol for a mixed-method, prospective observational study.
Review the original article for the full source wording and details.